GABA and movement disorders.
D000927:Anticonvulsants / Q000627:therapeutic use; D001418:Baclofen / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy / Q000503:physiopathology; D007538:Isoniazid / Q000627:therapeutic use; D009069:Movement Disorders / Q000503:physiopathology*; D009118:Muscimol / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology; D014635:Valproic Acid / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000502:physiology* / Q000627:therapeutic use
D000927:Anticonvulsants; D009118:Muscimol; C017985:progabide; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D001418:Baclofen; D007538:Isoniazid